140 related articles for article (PubMed ID: 32198886)
1. First Case of Refractory Colitis Caused by Ocrelizumab.
Sunjaya DB; Taborda C; Obeng R; Dhere T
Inflamm Bowel Dis; 2020 May; 26(6):e49. PubMed ID: 32198886
[No Abstract] [Full Text] [Related]
2. Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S; Heni M; Rauschenberg S; Lange K; Feisthammel J; Bläker H; Wiegand J
Z Gastroenterol; 2023 Nov; 61(11):1500-1503. PubMed ID: 36736346
[TBL] [Abstract][Full Text] [Related]
3. Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
Challa B; Esnakula AK
Histopathology; 2024 Apr; 84(5):765-775. PubMed ID: 38114289
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab for multiple sclerosis.
Drug Ther Bull; 2018 Jul; 56(7):80-84. PubMed ID: 30008443
[TBL] [Abstract][Full Text] [Related]
5. HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab.
Dudek MIR; Thies K; Kammenhuber S; Bösel J; Rösche J
J Neurol; 2019 Sep; 266(9):2322-2323. PubMed ID: 31115675
[No Abstract] [Full Text] [Related]
6. Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe.
Aun MV; Freua F; Marussi VHR; Giavina-Bianchi P
Front Immunol; 2022; 13():840238. PubMed ID: 35222433
[TBL] [Abstract][Full Text] [Related]
7. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
8. Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion.
Cicero S; Rissanen E; Carter K; Nguyen H; Petit R; Ellerin TB; Dhillon R; Singhal T
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34210799
[No Abstract] [Full Text] [Related]
9. Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Kim T; Brinker A; Croteau D; Lee PR; Baldassari LE; Stevens J; Hughes A; Tomaino J; deFonseka A; Altepeter T; Kortepeter CM
Mult Scler; 2023 Sep; 29(10):1275-1281. PubMed ID: 37706451
[TBL] [Abstract][Full Text] [Related]
10. Clindamycin-associated colitis.
Stroehlein JR; Sedlack RE; Hoffman HN; Newcomer AD
Mayo Clin Proc; 1974 Apr; 49(4):240-3. PubMed ID: 4817833
[No Abstract] [Full Text] [Related]
11. Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis.
Darwin E; Romanelli P; Lev-Tov H
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261571
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
14. Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
Alonso R; Galleguillos L
Mult Scler; 2021 Nov; 27(13):2118-2119. PubMed ID: 34449279
[No Abstract] [Full Text] [Related]
15. Longer-term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
Yeh EA; Bourdette D; Wiendl H
Neurology; 2021 Oct; 97(16):751-753. PubMed ID: 34475129
[No Abstract] [Full Text] [Related]
16. Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis.
Breneman AN; Eber AE; Haque H; Levine L; Askanase A; Riley CS; Pomeranz MK; Hassan D; Mancebo SE; Polin M; Melamed A; Bordone LA; Rosser M; Gockley A; Gallitano SM
J Low Genit Tract Dis; 2022 Apr; 26(2):189-191. PubMed ID: 35256568
[No Abstract] [Full Text] [Related]
17. Palmoplantar pustular psoriasis induced by ocrelizumab in a patient affected by multiple sclerosis.
Lappi A; Cammarata E; Nicola S; Borrelli P
Ital J Dermatol Venerol; 2022 Oct; 157(5):459-460. PubMed ID: 36213976
[No Abstract] [Full Text] [Related]
18. The recognition of pseudomembranous colitis as a clinical entity.
Scott AJ; Nicholson GI
Aust N Z J Med; 1974 Oct; 4(5):502-9. PubMed ID: 4532919
[No Abstract] [Full Text] [Related]
19. [Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].
Boyko OV; Khoroshylova II; Petrov SV; Lush NY; Guseva ME; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8. Vyp. 2):116-120. PubMed ID: 30160679
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
